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To evaluate whether parvovirus B19, a common human pathogen, was also involved in papillary thyroid carcinoma (PTC), 112
paraffin-embedded thyroid specimens of benign nodules, papillary, medullary and follicular carcinomas, and normal controls were
examined for B19 DNA and capsid protein by nested PCR, in situ hybridisation (ISH) and immunohistochemistry (IHC). The
expression of the nuclear factor-kB (NF-kB) was investigated by IHC. The results showed B19 DNA commonly exists in human
thyroid tissues; however, there were significant differences between PTC group and normal controls, and between PTC and
nonneoplastic adjacent tissues (Po0.001). The presence of viral DNA in PTC neoplastic epithelium was confirmed by laser-capture
microdissection and sequencing of nested PCR products. B19 capsid protein in PTC group was significantly higher than that of all the
control groups and nonneoplastic adjacent tissues (Pp0.001). Compared with control groups, the activation of NF-kB in PTC group
was significantly increased (Pp0.02), except for medullary carcinomas, and the activation of NF-kB was correlated with the viral
protein presence (P¼0.002). Moreover, NF-kB was colocalised with B19 DNA in the neoplastic epithelium of PTC by double
staining of IHC and ISH. These results indicate for the first time a possible role of B19 in pathogenesis of PTC.
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Papillary thyroid carcinoma (PTC) accounts for more than 80 per
cent of all the thyroid carcinomas in the United States and other
countries (Edwards et al, 2002; Mazzaferri and Massoll, 2002).
However, very little is known about the aetiology of PTC, although
several risk factors such as thyroid irradiation, high dietary iodine
intake, autoimmune diseases and genetic alterations have been
implicated (Schlumberger, 1998).
Infection with parvovirus B19 (B19) is a global concern, and it is
the aetiological agent of many diseases (Bultmann et al, 2003).
Some researchers have shown that B19 infection may play a role in
the pathogenesis of acute leukaemia (Kerr et al, 2003). However,
little literature on B19 involvement in solid tumours is available.
B19 is a small nonenveloped single-stranded DNA virus with a
genome size of 5596bp. The viral genome encodes three major
proteins: the nonstructural protein NS1 and two viral capsid
proteins VP1 and VP2 (Young and Brown, 2004). VP1 and VP2
were similar, except for an additional unique portion (VP1u) of
227 amino acids at its N terminus (Figure 1A). NS1 is cytotoxic to
host cells (Ozawa et al, 1988; Young and Brown, 2004). VP1 and
VP2, which form the icosahedral viral capsid, are immunogenic
(von Poblotzki et al, 1996; Corcoran and Doyle, 2004; Young and
Brown, 2004). It is reported that NS1 of B19 resembles tax protein
of T-cell leukaemia virus-1 (HTLV-1) and tat protein of human
immunodeficiency virus type 1 (HIV) in that they all play a part in
viral propagation and activate IL6 production through the Nuclear
factor-kB (NF-kB)-binding site in the IL6 promoter (Kerr, 2000).
Nuclear factor-kB can be activated rapidly by tax (Hiscott et al,
1997) and tat protein (Mhashilkar et al, 1997), respectively, and
activated NF-kB takes pivotal role in the HTLV-1-induced acute
leukaemia (Miwa et al, 1997) and HIV-induced Kaposi sarcoma
(Nasti et al, 1997). The activated NF-kB is also evident in PTC
(Bravo et al, 2003). We wonder whether B19 protein can activate
NF-kB and then plays a role in PTC.
We did a retrospective study to evaluate the possible role of
B19 infection in PTC patients. The presence of B19 genome and
B19 VP1/VP2 capsid proteins were examined in human thyroid
specimens from the consecutive patients with a spectrum of
thyroid disorders by nested PCR (nPCR), in situ hybridisation
(ISH), immunohistochemistry (IHC) and laser-capture micro-
dissection (LCM). The expression of NF-kB and its association
with virus infection were investigated by IHC and double labelling
of IHC and ISH, respectively. Evidence is presented for a potential
role of B19 in the pathogenesis of PTC.
MATERIALS AND METHODS
Tissue samples
A total of 112 paraffin-embedded thyroid tissues from the
consecutive patients with a spectrum of thyroid disorders were
retrieved from the pathology archives of Xijing Hospital from 2000
to 2005. There was no parvovirus epidemic before tissue sampling.
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sWe reviewed the patient’s charts to ensure that the patients with
pre-operative radiation or chemotherapy were excluded and no
one was immunocompromised. Two pathologists re-examined all
the cases to confirm diagnosis (JHW and GSH). The specimens
included 38 PTC tissues (30 out of 38 also had tumour-adjacent
nonneoplastic tissues), 16 normal thyroid tissues (obtained from
areas surrounding surgically removed adenomas), 39 benign
thyroid nodules (20 thyroid adenomas and 19 nontoxic multi-
nodular goiters), 9 thyroid medullary carcinomas (TMC) and 10
follicular thyroid carcinomas (FTC) tissues. Histological classifica-
tion of tumours was based on the World Health Organization
criteria. Kidney tissue of a B19-infected hydropic foetus, analysed
earlier by nPCR, ISH and IHC was used as positive tissue control
for each experiment. Another foetal kidney tissue of therapeutic
abortion without clinical, histological or serological evidence of
B19 infection was used as negative tissue control. Specimen
collection and the study procedures were approved by the Xijing
Hospital Ethics Committee.
DNA extraction, nested PCR and sequencing
DNA from the paraffin-embedded tissues was isolated by
proteinase K digestion followed by phenol–chloroform extraction
and ethanol precipitation, and finally, it was resuspended into
200ml of water.
B19 DNA was amplified by nPCR (Bultmann et al, 2003). The
first round PCR was carried out with the outer primers
(nucleotides 3370–3389 and 3659–3637, respectively). The second
round PCR was carried out with the inner primers (nucleotides
3400–3419 and 3572–3552, respectively), which amplified a region
of the B19 VP1/VP2 capsid protein sequence (Figure 1A). All the
nPCR reactions were performed in duplicate and in parallel with a
negative (water) and a positive control (pGEM-1/B19 plasmid
carrying the whole genome of B19, kindly provided by Professor
JP Clewley of Central Public Health Laboratory, London, UK). The
amplified DNA with the expected size (173bp) was purified with
Qiaquick PCR purification kit (Qiagene, Hilden, Germany) and
sequenced.
In situ hybridisation
The nPCR products of B19 DNA amplified by TaKaRa Pyrobest
DNA polymerase (TaKaRa Biotech) were purified and labelled to
generate the B19 DNA probe by random-primed incorporation of
digoxigenin-labelled dUTP using a Dig DNA labelling and
detection kit (Roche, Mannheim, Germany).
In situ hybridisation was performed according to previously
described methods (Morey et al, 1992). Briefly, paraffin sections of
4mm thickness were deparaffinised and hydrated, then placed in
0.2M HCl for 10min followed by digestion in 25mgml
 1
proteinase K (Merck, Darmstadt, Germany) for 10min at 371C.
After two washes with PBS, the sections were dehydrated, air-dried
and incubated with pre-hybridisation solution at 421C for 30min.
The sections and the B19 probe (with a final concentration of
200ngml
 1) were simultaneously denatured at 951C for 10min,
chilled on ice and incubated at 421C overnight. The slides were
then washed sequentially for 15min twice with SSC containing
10% (w/v) SDS, blocked with blocking buffer at 371C for 30min,
and incubated for 2h with anti-digoxigenin-alkaline phosphatase
conjugate. After two 15-min washes with washing buffer, the
sections were stained with NBT/BCIP (Roche, Mannheim,
Germany) solution until satisfactory blue signals were obtained.
The sections were then dehydrated and mounted with neutral
balsam before cover slipping. The duplicated sections of PTC were
hybridised with the pre-hybridisation mixture or digoxigenin-
labelled pBR328 DNA linearised with BamHI as negative controls.
Immunohistochemistry
Paraffin sections of 4mm thickness were deparaffinised and treated
with 3% (v/v) hydrogen peroxide to block endogenous peroxidase
activity. Heat-induced antigen retrieval was performed in 0.01M
sodium citrate (pH 6.0) and 10% (v/v) bovine serum albumin
(BSA; Sigma, St Louis, MO, USA) in PBS at room temperature
for 10min to block the nonspecific antibody-binding sites. Then
the sections were incubated overnight at 41C with the mouse
monoclonal antibody against the B19 proteins VP1/VP2 (1:20
dilution; Novocastra, Newcastle, UK) and the mouse monoclonal
antibody against the nuclear transcription factor subset NF-kB p65
(1:400 dilution; Santa Cruz Biotechnology, Santa Cruz, CA, USA),
respectively. A streptavidin–biotin–peroxidase complex kit
(SABC kit, Zymed, South San Francisco, CA, USA) was used to
detect the protein conjugates (Elias et al, 1989). Finally, the
sections were developed with a diaminobenzidine substrate
(Sigma, St Louis, MO, USA) and counterstained with haema-
toxylin. Serial sections of PTC were also run in parallel with the
replacement of the primary antibody with PBS and mouse IgG1
(AMS/Immunokontact, Abingdon, UK) as negative controls.
Double staining of immunohistochemistry and in situ
hybridisation
The expression of NF-kB was marked with mouse anti-NF-kB p65
monoclonal antibody by IHC. Then the section was hybridised
with B19-specific DNA probe.
Laser-capture microdissection and nested PCR
Five positive PTC specimens of B19 confirmed by nPCR were
subjected to LCM by the Leica Microsystems Wetzlar GmbH
(Wetzlar, Germany), according to the manufacturer’s protocols.
Serial sections (5mm) were prepared for each sample. The sections
were stained with haematoxylin and eosin. Each section was
overlaid with thermoplastic membrane and the cells were captured
by focal melting of the membrane by laser activation. Each of the
captured samples contained 50–100 cells. The Pico Pure DNA-
Extraction kit (Qiagene, Hilden, Germany) was used to isolate
DNA from laser-microdissected tissue fractions. Positive and
negative controls were included in nPCR. The amplified products
with the expected size (173bp) were purified and sequenced. The
individual sequence was then used in a BLAST search against
GenBank B19 sequences (National Center for Biotechnology
5 3 NS1 (436–2451)
123 45 67
173 bp
VP2 (3125–4787)
VP1 (2444–4787)
VP1u (2444–3125)
3400–3572
3370–3659
Figure 1 Schematic representation of human parvovirus B19 genome
and nested PCR amplification of parvovirus B19 DNA sequences in
papillary thyroid carcinomas, (A) NS1, VP1, and VP2 coding regions of the
B19 genome and the location and nucleotide positions of the primers for
nested PCR amplification. (B) Representative agarose gel electrophoresis
of nested PCR products. Lane 1: 100bp DNA ladder; lane 2: positive
control; lane 3: negative control; lanes 4, 5 and 6: positive samples. The
amplicons were approximately 173bp in size. Lane 7: negative sample.
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sInformation). Viral type was identified when nucleotide com-
parisons revealed an identity of 95% with the known type.
Statistical analysis
Statistical analysis was performed using Statistical Program for
Social Sciences (SPSS) software (version 11.0, SPSS Inc., Chicago,
IL, USA). The differences of gender and age distributions among
the groups were compared by Pearson w
2 test and analysis of
variance, respectively. Data from the experimental results were
analysed by Pearson w
2 test or Fisher’s exact test. Pairwise
comparison between PTC and nonneoplastic adjacent tissues was
made with McNemar’s exact Test. A two-sided P-value of o0.05
was considered statistically significant.
RESULTS
Clinical aspects and histopathology
The age of the 38 PTC patients ranged from 24 to 75 years old
(mean age: 43.5±12.8) and 29 of them were female. Statistical
analysis showed there was no significant difference between
PTC patients and control groups in age (P¼0.363) and gender
(P¼0.539). All the PTC patients and control cases were of Chinese
origin.
Histologically, all the PTC specimens included in this study
showed typical features of PTC with characteristic papillary
structure and/or nuclear features (Figure 2A). All the normal
thyroid tissues showed normal morphology. The samples from the
patients with nontoxic multinodular goiter were characterised by
many nodules, coexisting with atrophic and hyperplastic thyroid
follicles, as well as old haemorrhage and fibrosis in stroma. Single
nodule with a complete thin fibrous capsule composed of uniform
thyroid follicles made the diagnosis of thyroid adenomas. Spindle
or round cell tumour with amyloid stroma was the diagnostic
feature of TMC. Thyroid nodule containing groups of cells
invading the broad collagenous capsule and/or adjacent tissues
was the criteria for FTC.
B19 DNA exists in human thyroid tissues
Using nPCR, a DNA fragment of 173bp in size as predicted was
amplified in 37 out of 38 PTC specimens, 7 out of 16 normal
controls, 34 out of 39 benign thyroid nodules, 5 out of 9 TMC and
10 out of 10 FTC specimens (Figure 1B; Tables 1, 2 and 3). DNA
sequence analysis performed in four positive samples and the
nucleotide comparisons with the known type (GenBank gi:
9632996) revealed similarity of 95–97%, which confirmed that
they were amplified from B19 DNA. Statistically, the positive rate
of B19 DNA detected by nPCR in PTC group was significantly
higher than that in normal controls (P¼0.0001) and that in TMC
(P¼0.003), respectively.
In situ hybridisation for B19 DNA was performed in the tissue
sections of PTC and control specimens to confirm the local
infection of the virus and its cellular distribution. The positive ISH
signals were located in the nuclei of thyroid follicle epithelial cells
in different thyroid disorders and they were also seen in isolated or
scattered infiltrating lymphocytes. In PTC, the tumour cells
showed strong nuclear staining (Figure 2B and C), but no staining
or much weak intensity was observed in tumour-adjacent tissue
(Figure 2B) or the specimens of normal thyroid (Figure 2D). The
negative controls showed no staining (Figure 2E), whereas the
positive B19 control sample showed strong staining. The viral DNA
was detected in 30 out of 38 PTC, 2 out of 16 normal controls, 24
ABC
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Figure 2 In situ hybridization of parvovirus B19 DNA and IHC staining of B19 VP1/VP2 antigen in PTC. (A) Typical histopathological features of PTC.
(B and C) The tumour cells of PTC showed strong nuclear staining by ISH, but the staining was almost negative in epithelia in tumour-adjacent tissue (B)
and normal thyroid tissue (D). (E) Negative control (B19 probe was substituted by linearized pBR328 DNA). (F and G) Immunohistochemistry staining was
for B19 VP1/VP2 antigen in PTC specimen and positive signals were seen in the cytoplasm of many malignant thyroid epithelia of PTC, but not in tumour-
adjacent tissues. (H) No expression of VP1/VP2 antigen in normal thyroid samples. (I) Negative control (the primary antibody was replaced with mouse
IgGI). Original magnification;  40 (A, B and F);  200 (C–E, G–I).
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sout of 39 benign thyroid nodules, 1 out of 9 TMC and 7 out of 10
FTC specimens (Tables 1, 2 and 3). The result of ISH was similar to
that of nPCR (i.e. the distribution of B19 DNA in the thyroid
tissues detected by nPCR was identified by ISH). In addition, there
was significant difference between PTC (83.3%, 25 out of 30) and
tumour-adjacent tissues (23.3%, 7 out of 30, P¼0.0001 by
McNemar’s exact test).
B19 VP1/VP2-antigen is preferentially located in malignant
tissues of PTC
The positive IHC signals of B19 proteins were found in cytoplasm
of the follicle epithelial cells in different thyroid disorders. In most
PTC specimens, B19 viral protein immunoreactivity was detected
in neoplastic epithelium, but it was not seen in tumour-adjacent
tissues with normal appearance (Figure 2F and G). Normal
epithelium in normal thyroid samples demonstrated no expression
of VP1/VP2 antigen (Figure 2H) except only one case was weak
positive. The positive B19 control sample gave clear positive
staining, whereas the negative controls showed no evidence of IHC
staining (Figure 2I). The viral proteins were observed in 24 out of
38 PTC specimens, 1 out of 16 normal control thyroid tissues and 8
out of 39 benign thyroid nodules, but no viral protein was found in
TMC and FTC. Statistically, the positive rate of B19 VP1/VP2
antigen in PTC group was significantly higher than that in the
other groups (all Pp0.001). Pairwise comparisons showed a
significant difference in VP1/VP2 immunoreactivity between PTC
(63.3%, 19 out of 30) and tumour-adjacent tissues (10.0%, 3 out of
30, P¼0.0001 by McNemar’s exact test).
The activation of NF-jB is correlated with the VP1/VP2-
antigen expression
The positive signal of NF-kB in cytoplasm (Figure 3A and B) was
detected in 29 out of 38 PTC specimens by IHC. The expression of
NF-kB was greatly increased when compared with normal (2 out of
14, P¼0.0001), benign control groups (18 out of 37, P¼0.013),
FTC (1 out of 10, P¼0.0001) and tumour-adjacent tissue (1 out of
30, P¼0.0001). Nuclear translocation of NF-kB was found in 16
out of 38 PTC (Figure 3C), whereas only in 3 out of 37 benign
Table 1 PCR, in situ hybridization and immunohistochemical results for paraffin specimens of human papillary thyroid carcinoma and nonneoplastic-
adjacent tissues
IHC of NF-jB p65
ISH IHC Cytoplasmic Nuclear
Case Age, years Sex nPCR Tumour
Adjacent-
tumour Tumour
Adjacent-
tumour Tumour
Adjacent-
tumour Tumour
Adjacent-
tumour
13 6M + +      +   +  
23 4F +              
3 6 2 F++++ + + +   
46 1M + +      +    
53 9F + + N T + N T+    
6 4 1 F++++ + +    
7 4 7 F+++        
8 5 9M++++ +    +  
92 8F + +   +        
10 28 F + +           
11 49 F +           ++
12 24 F + + +    +   +  
13 33 F + +      +    
14 40 F + +   +   +   +  
15 62 F + + NT + NT +   +  
16 39 F +   NT   NT      
17 64 M +   NT   NT +   +  
18 37 F + + NT + NT      
19 60 M + +   +   +   +  
20 48 F + +   +   +   +  
21 30 M + + NT + NT +    
22 68 M + + NT + NT +   +  
23 30 F +   NT   NT +    
24 75 F + +   +   +   +  
25 35 F + +   +   +    
26 29 F + +   +   +    
27 33 F + +   +   +   +  
28 34 F + +   +   +    
29 47 F +       +    
30 42 F + +   +   +   +  
31 44 F + +   +   +   +  
3 2 3 3 F++++   +   +  
33 38 M + +   +   +    
3 4 3 7 F++++   +    
35 42 F + +   +   +    
36 41 F        +    
37 47 F +              
38 57 M + +   +   +   +  
IHC¼immunohistochemistry; ISH¼in situ hybridisation; NF-kB¼nuclear factor kappa B; nPCR¼nested PCR; NT¼no nonneoplastic-adjacent tissues.
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scontrol group (P¼0.001) and 1 out of 30 tumour-adjacent tissue
(P¼0.0001). None was observed in 14 normal controls (P¼0.002)
and 10 FTC (P¼0.02). There was no significant difference between
PTC and TMC in both cytoplasm (4 out of 9, P¼0.102) and
nuclear expression (4 out of 9, P¼1.000) of NF-kB.
In 33 cases of thyroid tissues that were positive for B19 VP1/VP2
protein, nuclear translocation of NF-kB was found in 13 cases,
whereas in 75 cases that were negative for VP1/VP2 protein, no
staining or immunostaining is present only in the cytoplasm in 65
cases. The nuclear translocation of NF-kB was well correlated with
the VP1/VP2-antigen expression (13 out of 33, P¼0.002).
The IHC-ISH double staining assay demonstrated the expression
of NF-kB p65 was colocalised with B19 DNA in cytoplasm (Figure
3D and E) or nuclei (Figure 3F) in the neoplastic cells of PTC.
The presence of viral DNA in PTC neoplastic epithelium
was confirmed by LCM and sequencing of nested PCR
products
Laser-capture microdissection was performed in two different
regions of five PTC samples. In the first region, PTC tumour cells
were dissected (Figure 4A1 and A2) and in the second region
glandular structures of tumour-adjacent tissues were dissected
(Figure 4B1 and B2). B19 genome was detected in all the
microdissected PTC sections by nested PCR, while only two were
detected in matched tumour-adjacent tissues (Figure 4C). Sequen-
cing analysis of the PCR amplicons showed that they were from
human parvovirus B19 gene.
DISCUSSION
Although nPCR was reported to be the most sensitive method,
PCR-based method alone for viral detection was not sufficient
(Pagano et al, 2004). In addition, PTC contains hypervascularised
fibrous connective tissue core which could interfere with the nPCR
results. Therefore, ISH together with IHC were performed to
confirm the local infection of the virus and its cellular distribution,
and the presence of viral DNA in PTC neoplastic epithelium was
confirmed by laser-capture microdissection and sequencing of
nested PCR products. Combination of these methods allowed us to
acquire definite histopathological information on B19 infection
while maintaining a high degree of sensitivity.
In the present study, both B19 genome and the virus capsid
proteins were frequently found in PTC tissues compared with
normal controls and nonneoplastic adjacent tissues. Meanwhile,
NF-kB was found to be activated, and it was well colocalised with
Table 2 PCR, in situ hybridization and immunohistochemical results for
paraffin specimens of human control thyroid tissues
B19 status IHC of NF-jB p65
Case Age, years Sex nPCR ISH IHC Cytoplasmic Nuclear
Normal controls
13 6 F +       
24 2 F      +  
36 7 F         
45 9 F +    ND ND
54 4 F + +   ND ND
62 5 F         
75 7 F + + + +  
84 9 F         
96 0M         
10 45 F +       
11 58 F +       
12 36 F         
13 51 F         
14 40 F +       
15 32 F         
16 48 F         
Benign thyroid nodules
14 1 F + + + +  
25 2 F + + +   
35 2 F + +   +  
42 8 F +       
55 6M +       
64 1M +       
72 2 F +       
85 9M +    +  
92 1 F + +     
10 58 F + + +   
11 54 F         
12 43 F      ND ND
13 39 F         
14 38 F + +     
15 42 F + + + +  
16 34 F +       
17 51 F +    +  
18 68 F + + + +  
19 41 F + +     
20 25 F + + + +  
21 28 F + +   ++
22 40 F + +     
23 53 F + + + + +
24 50 F + +   +  
25 35 F + +   +  
26 51 M      +  
27 44 M + +   ++
28 62 M + + + +  
29 21 F         
30 39 F + +   ND ND
31 54 F + +   +  
32 57 F +       
33 54 F + +   +  
34 41 F +       
35 46 F + +   +  
36 48 F + +     
37 51 F +       
38 32 F + +     
39 63 F + +   +  
Medullary thyroid carcinoma
13 3 F      ++
26 8 F         
36 8 F + +   ++
45 5M +    ++
53 0 F +       
63 9 F         
75 8M      ++
84 6 F +       
93 2 F +       
Table 2 (Continued)
B19 status IHC of NF-jB p65
Case Age, years Sex nPCR ISH IHC Cytoplasmic Nuclear
Follicular thyroid carcinoma
13 7 F + +     
27 2 F + +   +  
33 5M +       
45 7 F +       
55 6 F + +     
63 3 F + +     
76 4 F + +     
85 7 F + +     
94 1 F + +     
10 70 F +       
IHC¼immunohistochemistry; ISH¼in situ hybridisation; ND ¼not done as the
blocks were used up; NF-kB¼nuclear factor kappa B; nPCR¼nested PCR.
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sthe virus DNA in PTC tissues. Our findings revealed for the first
time that there is a novel link between B19 and PTC.
From our study, we found that the positive rate of B19 DNA was
high in benign thyroid nodules, FTC and PTC but low in normal
specimens. The different positive rates of B19 DNA could be due to
the preference for the rapidly dividing cells in S phase for virus
replication (Wolter et al, 1980). It is reported that the proliferative
activity of thyroid adenomas, nontoxic multinodular goiters,
follicular thyroid carcinoma and PTC is higher than that in
normal thyroid tissue (Saiz et al, 2002). Therefore, it is
comprehensible that B19 infection rates in these groups are higher
than that in normal thyroid tissue in this study.
Several members of the parvovirinae family, including H-1 virus
and minute virus of mice, have been shown to prevent tumour
formation by their oncotropism and oncolysis in laboratory
animals (Rommelaere and Cornelis, 1991). If B19 has oncotropic
and oncolytic properties, cell death should be obvious in PTC.
However, morphologically, necrosis is not a feature in PTC. On the
contrary, PTC often shows high proliferative activity (Saiz et al,
2002) and very low apoptotic index (Basolo et al, 1997). Therefore,
whether there is another explanation for the high frequency of B19
in PTC is in question.
In our study, we also found B19 DNA in TMC is less frequent
than that in the other thyroid diseases. This phenomenon could
result from the specific cell tropism of the B19 (Brown et al, 1993).
It is well known that B19 can only infect the cells that have
the proper receptors to which the virus can attach. Human
blood group P antigen has been confirmed to be the indispensable
cellular receptor for B19 infection (Brown et al, 1994). Human
thyroid follicle epithelia have been shown to have globoside
(Bouchon et al, 1985). Therefore, the expression of the specific
cellular receptor of B19 in these cells might account for
their susceptibility to B19 infection. Thyroid medullary carcinomas
originated from C cells, the low positive rate of B19 DNA in
TMC might be due to the absence of the specific cell receptor for
B19 infection. Further works are required to know the possible
reason.
It is in recent years that Norja et al (2006) have found that the
persistence of B19 genome in human tissues is ubiquitous and
lifelong. Another recent publication has demonstrated short
regions of sequence identity between B19 and human genes, and
these sequence identity may be biologically relevant to the
persistence of the viruses in human tissues (Kerr and Boschetti,
2006). Biopsies of tissues from synovium, skin, tonsils and liver
showed the presence of B19 genome; however, whether the virus
genome persists in thyroid tissue has not been determined.
Furthermore, without the expression of virus protein, the
persistence of B19 genome mainly denotes latent infection.
Usually, the detection of the persistence of viral genome with
expressed viral proteins in the tumour cells indicates a productive
infection of the virus in the cells and the potential involvement of
virus in pathways leading to the development and/or progression
of cancer (Pagano et al, 2004). In our study, we found that B19
DNA existed in 37 out of 38 PTC specimens and VP1/VP2-antigen
Table 3 Positive rate (%) of parvovirus B19 detected by nPCR, ISH and IHC in thyroid tissues of PTC and control groups
Group A B C D E
P-value
a
Disease
PTC
(n¼38)
Normal controls
(n¼16)
Benign nodules
(n¼39)
TMC
(n¼9)
FTC
(n¼10) A vs BA vs CA vs DA vs E
nPCR 97.4 43.8 87.2 55.6 100.0 0.0001 0.200 0.003 1.000
ISH 78.9 12.5 61.5 11.1 70.0 0.0001 0.095 0.0001 0.657
IHC 63.2 6.25 20.5 0.0 0.0 0.0001 0.0001 0.001 0.0001
FTC¼follicular thyroid carcinoma; IHC¼immunohistochemistry; ISH¼in situ hybridization; nPCR¼nested PCR; TMC¼thyroid medullary carcinoma.
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Figure 3 Immunohistochemical staining of NF-kB p65 and double labelling of NF-kB p65 and B19 DNA in the samples of PTC. (A) NF-kB
immunoreactivity in malignant tissues of PTC, but not in tumour-adjacent tissues. (B) Immunoreactivity of NF-kB in the cytoplasma of a PTC sample. (C)
Nuclear translocation of NF-kB in a PTC sample. (D) NF-kB IHC and B19 DNA ISH double staining signal in malignant epithelium in PTC, but the staining
intensity was much weak in epithelia in tumour-adjacent tissue. (E) Cytoplasmal expression of NF-kB p65 protein and robust nuclear presence of B19 DNA
in identical tumour cells. (F)C o e x p r e s s i o no fN F - kB p65 protein and B19 DNA in the nuclei of the tumour cells of PTC (black arrow). Original magnification:
 40 (A and D);  200 (B, C and E);  400 (F).
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swas preferentially located in tumour tissues of PTC, which
indicated that the virus was active in PTC lesions and the
productive infection of the virus might play some role, directly or
indirectly, as a cofactor in the pathogenesis of the tumour. In
addition, as benign thyroid proliferative disease may become
neoplastic (Pang et al, 1994; Bravo et al, 2003; Moore, 2006) and
some benign thyroid diseases without histopathological evidence
of PTC harbour similar molecular genetic changes with PTC
(Wirtschafter et al, 1997; Rhoden et al, 2006), the detection of B19
VP1/VP2 antigen in 6.25% of normal controls, 10% of tumour-
adjacent tissues, 20.5% of benign thyroid tissues and 63.2% of PTC
samples suggests that B19 expression may occur relatively early in
carcinogenesis of PTC.
Parvovirus is tightly dependent on host functions to complete
their life cycle (Wolter et al, 1980). Once the appropriate cellular
conditions are met, the virus starts its replication at the G1/S
transition, and a lytic or even productive infection can ensue.
Completion of the viral life cycle requires the assistance of various
cellular molecules (Raab et al, 2002); some of these have been
identified, however, much is unknown. In our study, all samples of
FTC were B19 negative by IHC, whereas they showed comparable
rates of positivity by PCR and ISH, which indicated that the virus
can infect thyroid epithelial cell but was active only in PTC lesions.
Papillary thyroid carcinoma and FTC are both carcinomas of
follicular cell origin; however, distinct susceptibility factors have
been involved in the pathogenesis of them. Presumably, some early
changes in PTC patients that promote parvovirus replication did
not exist in FTC. That is to say the different early changes in FTC
are unlikely to fulfill the requirements for B19 virus replication and
transcription.
Although the pathogenesis of PTC is not fully understood, it is
known that activation of NF-kB, a mediator for viral-induced
tumorigenesis (Mosialos, 1997), plays a critical role in the process
of thyroid cell transformation (Visconti et al, 1997). In our study,
we found the NF-kB was overexpressed and activated in PTC, and
the activation of NF-kB was correlated with the expression of viral
protein (13 out of 33, P¼0.002). These results support the
hypothesis that B19 may play a role in the pathogenesis of PTC;
however, further work is required to address the association
between NF-kB and B19 protein, and between B19 and PTC. The
present results showed TMC also had a substantial percentage of
NF-kB nuclear expression. This phenomenon is in agreement with
prior studies in medullary carcinomas (Ludwig et al, 2001). A
variety of stimuli can initiate different signalling pathways leading
to NF-kB activation, and specific point mutations of the RET
proto-oncogene in TMC is responsible for NF-kB activation and
RET-mediated carcinogenesis.
Indeed, determining the relationship between a virus infection
and a cancer is not an easy task. Based on our findings that both
B19 nucleic acids and proteins are in a significantly high
proportion in malignant tissues of PTC, we believe that there is
some correlation between parvovirus B19 and PTC. However,
further work is required to investigate the exact role of B19
infection in PTC.
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Figure 4 Laser-capture microdissection and nested PCR amplification for parvovirus B19 DNA in papillary thyroid carcinoma. (A–A1) Tumour cells of
papillary thyroid carcinoma were microdissected. (B–B1) Glandular structures of tumour-adjacent tissue of PTC were microdissected. (C) Products of
nested PCR from the microdissected tissues. Lane M: 100bp DNA ladder. Lanes 1–5: specimens from neoplastic tissues; lanes 10–50: tumour-adjacent
tissues; lane N: negative control; lane P: positive control. The amplicons were approximately 173bp in size. Original magnification:  400 (A–A1);  200
(B–B1).
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